Healthcare • NYSE
According to Zyberno, LABCORP HOLDINGS INC. (LH) is not a buy — AVERAGE BUSINESS (53/100) with a negative Margin of Safety of -100.0% and a Brina Gap of -7.9% showing the market already prices in more growth than the fundamentals support.
According to Zyberno's DCF model, LABCORP HOLDINGS INC. (LH) trades at $336.03 against an estimated intrinsic value per share of $75.55 — a -100.0% Margin of Safety based on Owner Earnings of $1.38B TTM, projected at -21.2% growth for 10 years with a 2.5% terminal growth rate. The Brina Gap of -7.9% weakens the case: based on the company's ROIC (9.3%) and reinvestment rate (24.8%), the business can fundamentally grow at 2.3% — but the current enterprise value implies the market expects 10.2%. This places LH in the Expensive Hype quadrant of the Brina Matrix, the most fragile combination — overvalued on cash AND overpriced on growth. Zyberno's model translates this into a 5-year expected return of -40.6% annually.
Over the trailing twelve months, LH generated $1.38B in Owner Earnings. Capital was deployed as follows: $98.00M returned via share buybacks, $238.80M paid as dividends, $429.50M invested in capital expenditures. Reinvestment rate: 24.8%. Owner Earnings have declined at 21.2% annually over the trailing five years using log-linear regression.